Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-368 combination therapy study in recurrent/metastatic head and neck squamous cell carcinoma
NL-OMON49382Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of revdofilimab, tilsotolimod, paclitaxel and budigalimab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability, Pharmacokinetics of ABBV-368, tilsotolimod, and budigalimab and 1 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
revdofilimabtilsotolimodpaclitaxelbudigalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON49382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49382.